What is key point 1 about "Gentex Corp general counsel Ryan sells $223k in shares"?

Gentex general counsel Ryan sold over $580,000 worth of company shares

What is key point 2 about "Gentex Corp general counsel Ryan sells $223k in shares"?

Ryan also acquired nearly 37,000 shares, including performance-based awards

What is key point 3 about "Gentex Corp general counsel Ryan sells $223k in shares"?

Gentex beat EPS expectations but missed revenue targets in Q4 2025

What is key point 4 about "Gentex Corp general counsel Ryan sells $223k in shares"?

UBS lowered price target but maintained Neutral rating on Gentex

2/20/2026 | USA | economy | ✓ Verified - investing.com

Gentex Corp general counsel Ryan sells $223k in shares

#Gentex Corp #Insider Trading #Ryan Scott P. #NASDAQ:GNTX #Q4 Earnings #UBS Rating #Share Sales

📌 Key Takeaways

Gentex general counsel Ryan sold over $580,000 worth of company shares
Ryan also acquired nearly 37,000 shares, including performance-based awards
Gentex beat EPS expectations but missed revenue targets in Q4 2025
UBS lowered price target but maintained Neutral rating on Gentex

📖 Full Retelling

Gentex Corp general counsel Ryan Scott P. sold a total of 23,423 shares of company stock on February 17, 2026, in transactions valued at approximately $581,556, according to a Form 4 filing with the Securities and Exchange Commission. The insider trading activity consisted of two separate sales: 9,024 shares sold at $24.7302 per amounting to $223,165, and an additional 14,399 shares disposed at $24.89 each totaling $358,391. Despite these sales, Ryan also acquired 36,782 shares of Gentex Corp common stock, including 25,782 performance-based shares granted based on long-term performance incentives and 11,000 shares that will vest 100% three years from the grant award date. This insider activity comes as Gentex Corporation reported its fourth-quarter 2025 earnings with a slight beat on earnings per share but a minor miss on revenue. The company achieved an EPS of $0.43, surpassing forecasts by 2.38%, while revenue came in at $644.4 million, falling short of expectations by 0.98%. In response to these results, UBS lowered its price target for Gentex to $25.00 from $26.00 while maintaining a Neutral rating, noting that the fourth-quarter results were 'better than headline' with an 8% EBIT beat despite some one-time headwinds affecting the EPS figure.

🏷️ Themes

Insider Trading, Corporate Performance, Analyst Response

📚 Related People & Topics

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗

Gentex

Topics referred to by the same term

Gentex or Gentex Corporation may refer to:

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared

👤 New York Stock Exchange 4 shared

👤 Rachel Haurwitz 3 shared

🌐 ZWS 2 shared

🌐 Biopharmaceutical 2 shared

View full profile

Deep Analysis

Why It Matters

Gentex's general counsel sold shares worth $223k, indicating insider activity that may signal management's view on the company's valuation. The sale, combined with other trades, could influence investor sentiment and stock volatility.

Context & Background

Gentex Corp is a manufacturer of automotive and industrial safety products
The company reported Q4 2025 earnings slightly above EPS estimates but below revenue forecasts
UBS lowered its price target to $25.00 after the earnings release

What Happens Next

Investors will monitor future insider transactions and the company's guidance for 2026. Analysts may adjust valuations based on the new price target and potential earnings momentum.

Frequently Asked Questions

What shares did Ryan Scott P. sell?

He sold 9,024 shares at $24.7302 each, totaling about $223,165, and also disposed of 14,399 shares at $24.89 each, totaling $358,391.

Did Ryan Scott P. also purchase shares?

Yes, he acquired 36,782 shares, including 25,782 performance-based shares that vest after three years.

How did Gentex's Q4 2025 results affect analyst outlook?

UBS lowered its price target to $25.00 from $26.00 but kept a neutral rating, citing better-than-headline earnings but revenue miss and one-time headwinds.

Original Source

              try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nvidia and OpenAI close to finalizing smaller, $30 bln investment- FT U.S. stocks end lower after hawkish Fed minutes; Walmart guidance falls short Gold largely flat as investors weigh geopolitical tensions, hawkish Fed minutes Berenberg sees more than 50% upside in this small-cap software stock (South Africa Philippines Nigeria) Gentex Corp general counsel Ryan sells $223k in shares By Investing.com Insider Trading Published 02/20/2026, 02:02 AM Gentex Corp general counsel Ryan sells $223k in shares 0 GNTX -2.32% Gentex Corp (NASDAQ:GNTX) General Counsel Ryan Scott P. sold a total of 9,024 shares of common stock on February 17, 2026, at a price of $24.7302, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the sale was approximately $223,165. The filing also indicates that Ryan Scott P. disposed of 14,399 shares of common stock at a price of $24.89, totaling $358,391. Additionally, Ryan Scott P. acquired 36,782 shares of Gentex Corp common stock. 25,782 shares are performance-based shares where the total number of shares granted were based on long term performance incentives and 11,000 shares vest 100% three years from grant award date. In other recent news, Gentex Corporation reported its fourth-quarter 2025 earnings, with a slight beat on earnings per share but a minor miss on revenue. The company achieved an EPS of $0.43, surpassing the forecast of $0.42, representing a 2.38% surprise. However, revenue came in at $644.4 million, which was below the anticipated $650.81 million, marking a 0.98% miss. UBS responded to these results by lowering its price target for Gentex to $25.00 from $26.00, while maintaining a Neutral rating on the company’s shares. UBS noted that Gentex’s fourth-quarter results were "better than headline" with an 8% EBIT beat, despite earnings per share meeting expectations due to "some one-time headwinds." These developments reflect the current...
            

Read full article at source

Source

investing.com